Tel: 1-631-626-9181 (USA)   44-207-097-1828 (Europe)
  Email:

CBpromise   

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

Vaccinia Virus (VACV) Service

Oncolytic virus (OV) has become a promising approach in cancer treatment due to their less toxicity, higher specificity and efficiency after being engineered. Various types of OVs have been developed and applied in clinical trials including vaccinia virus (VACV)-derived OVs. Creative Biogene is offering vaccinia virus (VACV) service to help researchers create fit-for-project recombinant VACVs that can be used in OV-based cancer research.

VACV Introduction

Vaccinia virus (VACV) is a large enveloped, double-stranded DNA virus in the genus of Orthopoxvirus of the family Poxviridae. The VACV genome is comprised of approximately 190,000 nucleotides which encodes approximately 250 genes.

Vaccinia virus (VACV) Figure 1. Vaccinia virus (VACV)

VACV is one of the most commonly developed oncolytic vectors. There are several features make VACV a promising oncolytic vector which include excellent lytic activity, natural and broad tumor tropism as well as well-known and easy-manipulating genome structure etc. JX-594, also known as Pexa-Vec and INN pexastimogene devacirepvec, is an advanced, recombinant oncolytic vector which is modified to be GM-CSF (granulocyte-macrophage colony-stimulating factor) expression and TK (thymidine kinase) deletion. Data from clinical trials has showed good profiles of JX-594 in destroying cancer cells through its lysis ability as well as GM-CSF induced anti-tumour immune responses. Now more novel oncolytic VACVs are underdevelopment with the aim to improve oncolytic specificity, safety and efficacy.

VACV Design & Production

Oncolytic viruses are generally modified by inserting exogenous therapeutic gene(s) or deleting endogenous toxic gene(s) to decrease their toxicities and enhance their anti-tumor activities. Creative Biogene owns state-of-the-art facilities and professional scientists with years of experience in manipulating various types of virus genomes. So far, we have developed an efficient way to generate recombinant VACVs. Whether you want to insert and / or delete GOI(s) in VACVs, contact us today at or 1-631-626-9181, we are ready and can always help you.

Green fluorescent image of cells infected with VACV-GFP. Figure 2. Green fluorescent image of cells infected with VACV-GFP.

Applications

  • Gene delivery
  • Study and design VACV-based oncolytic viruses

Our Service Includes

Service workflow Figure 3. Service workflow

References

  1. Vanderplasschen A; Pastoret PP. The Uses of Poxviruses as Vectors. Curr Gene Ther. 2003 Dec;3(6):583-95.
  2. McFadden G. Poxvirus tropism. Nat Rev Microbiol. 2005 Mar;3(3):201-13.
  3. Guse K, Cerullo V, Hemminki A. Oncolytic vaccinia virus for the treatment of cancer. Expert Opin Biol Ther. 2011 May;11(5):595-608.
  4. Al Yaghchi C, Zhang Z, Alusi G, Lemoine NR, Wang Y. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy. 2015;7(12):1249-58.

Quick Inquiry

   Please input "biogene" as verification code.